Ιoannis Kotsianidis

ORCID: 0000-0001-7668-0186
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Immune cells in cancer
  • Hemoglobinopathies and Related Disorders
  • Multiple Myeloma Research and Treatments
  • Immunodeficiency and Autoimmune Disorders
  • Hematological disorders and diagnostics
  • Histone Deacetylase Inhibitors Research
  • Pneumocystis jirovecii pneumonia detection and treatment
  • CNS Lymphoma Diagnosis and Treatment
  • Epigenetics and DNA Methylation
  • CAR-T cell therapy research
  • Acute Lymphoblastic Leukemia research
  • T-cell and B-cell Immunology
  • Blood groups and transfusion
  • Hematopoietic Stem Cell Transplantation
  • Platelet Disorders and Treatments
  • Eosinophilic Disorders and Syndromes
  • Bone and Joint Diseases
  • Viral-associated cancers and disorders
  • Protein Degradation and Inhibitors

Democritus University of Thrace
2016-2025

University Hospital of Alexandroupolis
2016-2025

Trakia University
2022-2023

Hellenic Oncology Research Group
2016-2020

Assistance Publique – Hôpitaux de Paris
2017

Inserm
2017

Centre Hospitalier Universitaire Henri-Mondor
2017

Université d'Angers
2017

Université Paris Nanterre
2017

Université Paris-Est Créteil
2017

BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters cytogenetic abnormalities. Somatic gene mutations not yet used in risk of patients with MDS. METHODS: To develop a clinical-molecular prognostic model (IPSS-Molecular [IPSS-M]), pretreatment diagnostic or peridiagnostic samples from 2957 MDS were profiled 152 genes. Clinical...

10.1056/evidoa2200008 article EN NEJM Evidence 2022-06-12

10.1038/s41591-020-1008-z article EN Nature Medicine 2020-08-03

Probiotic microorganisms such as lactic acid bacteria (LAB) exert a number of strain-specific health-promoting activities attributed to their immunomodulatory, anti-inflammatory and anti-carcinogenic properties. Despite recent attention, our understanding the biological processes involved in beneficial effects LAB strains is still limited. To this end, present study investigated growth-inhibitory Lactobacillus casei ATCC 393 against experimental colon cancer. Administration live (as well...

10.1371/journal.pone.0147960 article EN cc-by PLoS ONE 2016-02-05

The implication of T cells in the pathogenesis idiopathic pulmonary fibrosis (IPF) is controversial. CD4(+)CD25(+)FOXP3(+) regulatory (Tregs) are pivotal maintaining immune homeostasis, but their role IPF pathophysiology has not yet been studied.To explore Treg dynamics and function IPF.Treg levels were analyzed by flow cytometry peripheral blood (PB) bronchoalveolar lavage (BAL) 21 patients with IPF, 35 lung diseases other than (patients without IPF), 20 collagen vascular parenchymal...

10.1164/rccm.200812-1936oc article EN American Journal of Respiratory and Critical Care Medicine 2009-04-03

Background Sepsis is associated with systemic inflammatory responses and induction of coagulation system. Neutrophil extracellular traps (NETs) constitute an antimicrobial mechanism, recently implicated in thrombosis via platelet entrapment aggregation. Methodology/Principal Findings In this study, we demonstrate for the first time localization thrombogenic tissue factor (TF) NETs released by neutrophils derived from patients gram-negative sepsis normal treated either serum septic or...

10.1371/journal.pone.0045427 article EN cc-by PLoS ONE 2012-09-19

study objectives: Several lines of evidence suggest immune system derangement in obstructive sleep apnea syndrome (OSAS) patients.However, no data exist on the long-term effect continuous positive airway pressure (CPAP) treatment systemic immunity.Hence, we sought to evaluate this various immunological parameters OSAS patients.design: Prospective case series.setting: Sleep unit a general hospital.Patients: Newly-diagnosed, nonsmoking, otherwise healthy male patients (n = 52) were evaluated...

10.1093/sleep/32.4.537 article EN SLEEP 2009-04-01

Background The role of neutrophils in tumour biology is largely unresolved. Recently, independent studies indicated either neutrophil extracellular traps (NETs) or Tissue Factor (TF) involvement cancer and associated thrombosis. However, their individual combined colonic adenocarcinoma still unexplored. Methods Colectomy tissue specimens variable number draining lymph nodes were obtained from ten patients with the colon. NETs deposition presence as well TF expression examined by...

10.1371/journal.pone.0154484 article EN cc-by PLoS ONE 2016-05-02

The role of dietary probiotic strains on host anti-cancer immune responses against experimental colon carcinoma was investigated. We have previously shown that Lactobacillus casei administration led to tumor growth suppression in an cancer model. Here, we investigated the underlying mechanisms involved this tumor-growth inhibitory effect. BALB/c mice received daily live lactobacilli per os prior establishment a syngeneic subcutaneous CT26 tumor. Tumor volume, cytokine production, T cell...

10.3390/cancers12020368 article EN Cancers 2020-02-05

SummaryBackgroundIn our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer survival compared who receive red blood cell transfusion (RBCT). In this study, a follow up time and more included, aimed to assess long-term effects health-related quality of life (HRQoL) exposure or without RBCT syndromes.MethodsThe EUMDS Registry is non-interventional,...

10.1016/s2352-3026(24)00350-8 article EN cc-by The Lancet Haematology 2025-02-01

Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated erythropoiesis-stimulating agents (ESAs), a response rate of approximately 50%. Second-line treatments, including hypomethylating (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression overall survival (OS) is unknown. Here, we analyzed outcome the second-line treatments. Patients Methods We examined...

10.1200/jco.2016.71.3271 article EN Journal of Clinical Oncology 2017-03-28

Generalized pustular psoriasis (GPP) is a severe type of accompanied by systemic and often life-threatening manifestations. The efficacy the interleukin (IL)-1 antagonist anakinra in cases GPP underscores role IL-1 disease pathogenesis. We present case middle-aged man who developed an abrupt form with eosinophilia cholestatic hepatitis. patient received salvage treatment combination glucocorticoids, hydroxyurea imatinib, while administration inhibitor resulted remission hepatitis significant...

10.1111/bjd.14685 article EN British Journal of Dermatology 2016-04-23

Idiopathic pulmonary fibrosis represents a lethal form of progressive fibrotic lung disorder with gradually increasing incidence worldwide. Despite intense research efforts its pathogenesis is still elusive and controversial reflecting in the current disappointing status regarding treatment.We report first protocol proposal prospective, unicentric, non-randomized, phase Ib clinical trial to study safety tolerability adipose-derived stem cells (ADSCs) stromal vascular fraction (SVF) as...

10.1186/1479-5876-9-182 article EN cc-by Journal of Translational Medicine 2011-10-21

It has been shown that bone marrow mesenchymal stromal cells (MSCs) from patients with myelodysplastic syndromes (MDSs) display defective proliferative potential. We have probed the impaired replicative capacity of culture-expanded MSCs in MDS (n=30) compared healthy subjects (n=32) by studying senescence characteristics and gene expression associated WNT/transforming growth factor-β1 (TGFB1) signaling pathways. also explored consequences patient MSC potential investigating their...

10.1089/scd.2013.0283 article EN Stem Cells and Development 2014-03-12

Immune regulation is a finely balanced process of positive and negative signals. PD-L1 its receptor PD-1 are critical regulators autoimmune, antiviral antitumoural T cell responses. Although the function predominant membrane-bound form well established, source biological activity soluble (sPD-L1) remain incompletely understood. Here, we show that sPD-L1 in human healthy tissues tumours produced by exaptation an intronic LINE-2A (L2A) endogenous retroelement CD274 gene, encoding PD-L1, which...

10.7554/elife.50256 article EN cc-by eLife 2019-11-15

Lactobacillus paracasei K5 is a lactic acid bacteria (LAB) strain, isolated recently from feta-type cheese. Its probiotic potential has been demonstrated in series of established vitro tests. Moreover, incorporation L. as starter culture offered organoleptic and technological advantages to novel fermented food products. In the present study, further investigation activity was performed its mechanisms action were investigated. Employing quantitative analysis confocal, fluorescent microscopy...

10.3920/bm2017.0183 article EN Beneficial Microbes 2018-10-24

Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated red blood cell transfusions is usually reduced, but it unclear whether transfusion dose density an independent prognostic factor. The European MDS Registry collects prospective data at 6-monthly intervals from newly diagnosed in 16 countries and Israel. Data on the - cumulative received end each interval divided by time since beginning which first was were analyzed using proportional hazards...

10.3324/haematol.2018.212217 article EN cc-by-nc Haematologica 2019-06-06
Thomas Chatzikonstantinou Lydia Scarfò Georgios Karakatsoulis Eva Minga Dimitra Chamou and 95 more Gloria Iacoboni Jana Kotašková Christos Demosthenous Lukáš Smolej Stephen P. Mulligan Miguel Alcoceba Salem Al‐Shemari Thérèse Aurran‐Schleinitz Francesca Bacchiarri Mar Bellido Fontanet Bijou Anne Calleja Ángeles Medina Mehreen Ali Khan Ramona Cassin Sofia Chatzileontiadou Rosa Collado Amy Christian Zadie Davis Maria Dimou David Donaldson Gimena dos Santos Barbara Dreta Maria Efstathopoulou Shaimaa El‐Ashwah Alicia Enrico Alberto Fresa Sara Galimberti Andrea Galitzia Rocío García‐Serra Eva Gimeno Isabel González-Gascón-y-Marín Alessandro Gozzetti Valerio Guarente Romain Guièze Ajay Gogia Ritu Gupta Sean Harrop Eleftheria Hatzimichael Yair Herishanu José‐Ángel Hernández‐Rivas Luca Inchiappa Ozren Jakšić Susanne R. Janssen Elżbieta Kalicińska Kamel Laribi Volkan Karakuş Arnon P. Kater Bonnie Kho Maria Kislova Εliana Konstantinou Maya Koren‐Michowitz Ιoannis Kotsianidis Robert J. Kreitman Jorge Labrador Deepesh Lad Mark‐David Levin Ilana Levy Thomas Longval Alberto López‐García Juan Marquet Lucia Martin-Rodríguez Marc Maynadié Stanislava Mašlejová Carlota Mayor‐Bastida Biljana Mihaljević Ivana Milošević Fatima Mirás Riccardo Moia Marta Morawska Roberta Murru Uttam Kumar Nath Almudena Navarro‐Bailón Ana Carla Oliveira Jacopo Olivieri David Oscier Irina Panovska-Stavridis Maria Papaioannou Tomáš Papajík Zuzana Kubová Punyarat Phumphukhieo Cheyenne Pierie Anna Puiggros Lata Rani Gianluigi Reda Gian Matteo Rigolin Rosa Ruchlemer Marcos Daniel de Deus Santos Mattia Schipani Annett Schiwitza Yandong Shen Martin Šimkovič Svetlana Smirnova Dina Sameh Soliman Martin Špaček

Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, impact CLL-related factors and CLL-directed treatment is still unclear represents focus this work. We conducted retrospective international multicenter study assess incidence OMs detect potential in 19,705 patients CLL, small lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 2016. Data collection took...

10.1016/j.eclinm.2023.102307 article EN cc-by-nc-nd EClinicalMedicine 2023-11-01
Coming Soon ...